Our mission
Epiopharm GmbH is a pharmaceutical company working on first-in-class anti-inflammatory therapies to improve the lives of patients suffering from chronic inflammatory disease. The company therefore develops highly efficient small organic molecules with oral bioavailability.
Programs
The core purpose of Epiopharm is the research and development of novel anti-inflammatory medicines. Presently, the company is in the stage of preclinical development with highly efficient small organic molecules that display oral bioavailability.
Services
Epiopharm serves as advisor and counselor to businesses and institutions in the biotech and pharmaceutical sector.
The company further provisions services to community pharmacies by an experienced Swiss-licensed pharmacist with knowledge of various POS-systems, conventional and traditional pharmaceutical therapies, and state of the art pharmaceutical compounding.
Please direct your inquiry to info@epiopharm.ch.
Dr. Antonia Hirt
Chief Executive Officer
About
Epiopharm was founded in 2020 in the St. Gallen - Bodensee area in eastern Switzerland by Antonia Hirt.
Antonia completed a PhD in Pharmaceutical Sciences from the ETH Zurich, which she performed with support of the Scholarship Fund of the Swiss Chemical Industry (SSCI) and Innosuisse. Her Master's thesis was awarded the prestigious ETH medal. During her time at ETH she acquired experience in early-stage drug discovery projects and profound knowledge on the preclinical investigations of small organic compounds. Antonia further is a pharmacist and holds a license for several Swiss cantons.
In 2021 Antonia made the Forbes 30 Under 30 list.